Amanote Research
Register
Sign In
Brentuximab Beats Standard Therapies for CTCL
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2017-012
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
January 24, 2017
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Response to Brentuximab Vedotin by Cd30 Expression: Results From Five Trials in Ptcl, Ctcl, and B-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pcn175 - Brentuximab Vedotin Compared With Standard Therapy for Patients With Advanced-Stage Hodgkin’s Lymphoma: A Cost-Effectiveness Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Interdiction of Sphingolipid Metabolism to Improve Standard Cancer Therapies
Advances in Cancer Research
Cancer Research
Oncology
Quality Assessment for Delta and Theta Binaural Beats
Journal of Engineering and Applied Sciences
Engineering
Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
PC08.02 Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients With NSCLC Oligometastese (CON)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
PC08.01 Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients With NSCLC Oligometastese (PRO)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Bendamustine-Brentuximab: Bridging to Transplant
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Significance of Ectopic Beats.
BMJ
